Introduction
One of the major problems in cancer therapy is in defining specific agents, or combinations of agents, which are highly toxic to cancer cells yet have limited toxicity on normal non-transformed cells. Recently a number of novel chemical or biological agents have been reported to possess these characteristics 1 The proteasome inhibitor PS-341 has been shown to be toxic to multiple solid and hematological cancer cell lines in vitro and in vivo. [1] [2] [3] Of significance is the differential effects PS-341 exhibits on these tumor cells over normal cycling cells. The enhanced sensitivity of the cancer cells towards PS-341 provides its therapeutic window, which can be especially large in hematological malignancies. 4 In addition, the therapeutic utility of PS-341 has recently been confirmed in multiple clinical trials focusing on both solid and hematological cancer. [5] [6] [7] Treatment of tumor cells with PS-341 results in multiple biological effects including inhibition of the cell cycle, increased apoptosis, changes in cell adherence and inhibition of NF-B activation. 8 Indeed, the inhibition of NF-B may even underlay some of the proapoptotic effects of PS-341. Due to the pivotal role the proteasome plays in apoptosis, inhibitors of this enzyme, such as PS-341, provide an opportunity for exploring synergy between proteasome inhibition and other apoptosis-inducing agents.
Tumor necrosis factor-related apoptosis inducing ligand (TRAIL) has also been proposed as a novel anticancer agent due to its ability to induce apoptosis in tumor cells, while having little effect on a range of normal cells. 9 Interestingly, on binding to its receptors, TRAIL not only causes FADD recruitment and caspase activation but can also result in the activation of NF-B.
NF-B is a key transcriptional regulator of several genes involved in apoptosis. 10 
NF-B can
only.
For personal use at PENN STATE UNIVERSITY on February 20, 2013 . bloodjournal.hematologylibrary.org From activate the transcription of antiapoptotic genes that include cIAP-1, cIAP-2, XIAP, the TNFreceptor associated factor TRAF1, the antiapoptotic protein IEX-IL, as well as the Bcl-2 homologues, A1/Bf1, and Bcl-Xl. [11] [12] [13] [14] Indeed, transfection of various combinations of cIAP-1, cIAP-2, TRAF-1 and TRAF -2 can protect certain cells against apoptosis mediated by TNF-or etoposide. 11 NF-B is also reported to increase expression of c-FLIP, which can block extrinsic apoptosis via death receptors. 15 Furthermore, the blocking of NF-B activation by either nondegradable forms of I -B or proteasome inhibitors can enhance the apoptotic response of some tumor cells to TNF-or TRAIL in vitro. [16] [17] [18] However, studies on both human renal carcinoma cells and various transfectants of 293 cells suggest that inhibition of NF-kB activity does not modulate sensitivity to TRAIL in all cells. 19, 20 Additionally, although the in vitro data is encouraging, no studies to date have described whether combinations of proteasome inhibitors and death ligands such as TRAIL could provide therapeutic benefit in relevant animal models in vivo.
Patients with acute leukemia, lymphomas 21 and testicular cancer 22 have been cured by high dose chemotherapy (HDC). The major dose limiting toxicity of HDC or radiation therapy is bone marrow suppression, therefore bone marrow transplantation (BMT) has been used following high doses of these regimens. 23 This approach has also been applied to breast cancer patients using hematopoietic stem cell transplantation (HSCT), 24 although whether this therapy provides significant benefit has proven controversial. 25 Nonetheless, relapse remains an important barrier to successful BMT, and one potential problem involves tumor cell contamination of the autologous BMT. Since small numbers of tumor cells may persist in any autologous bone marrow inoculum used for hematopoietic rescue, novel methods allowing for only.
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Using the murine C1498 acute myeloid leukemia tumor model and the murine renal carcinoma Renca, we have assessed the effects of PS-341 and TRAIL on the death of these tumor cells in vitro. Furthermore, we have attempted to purge C1498 tumor cells from bone marrow:tumor cell mixtures. These bone marrow:tumor cell mixtures have then been transferred to irradiated syngeneic recipient mice. This model allowed us to estimate the efficacy with which combinations of PS-341 and TRAIL could destroy tumor cells. However, it also allowed for an analysis of the toxicity of the PS-341 plus TRAIL combination, since upon transfer of the bone marrow to irradiated recipients, survival of the donor bone marrow stem cells would be necessary for complete hematopoietic reconstitution. Physics, Silver Spring, MD) as previously described. 26 The cells were pretreated with various concentrations of PS-341 for 2 hours prior to the addition of TRAIL. In caspase inhibition studies, the caspase inhibitor zVAD-FMK or control zFA-FMK at a final concentration of 50 µM were also added 2 hours prior to TRAIL. After 18 hours at 37 0 C, the release of isotope from target cells was calculated as previously described. 26 In some assays, as an alternative to isotope labeling, cell viability was assessed by the addition of the novel tetrazolium compound (3-[4,5-
Promega Corp. Madison, WI for 4 hours, followed by measuring absorbance at 450 nm on an Elisa microplate reader. Apoptosis was also estimated using the Apoptosis Detection Kit (R + D Systems, Minneapolis, MN) as described by the manufacturers. C1498 cells were treated for 18
hours with PS-341 and/or TRAIL as described previously. Cells were then isolated and Annexin V staining and propridium iodide uptake were then analyzed on a FACScan as previously described. 27 For long-term clonal survival assays, C1498 cells (10 5 c/ml) were incubated for 18 was always performed at each time point.
Proteasome inhibition assay
The proteasome assay was performed essentially as previously described. 28 Briefly, C1498 cells Each treatment was performed at least in quadruplicate and the mean value for each of the treatment on a plate was expressed as a percentage/fold of the change relative to the controls on the same plate.
Western blotting
Western blotting was performed using Novex minigels as previously described. 29 Briefly, C1498
only. 
Statisitics
All experiments were performed at least 3 times with similar findings. The significance of differences between experimental and control groups was determined using the Student's t test.
The significance of differences between experimental groups for survival studies in vivo was determined by the log rank test.
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Results

Effects of PS-341 and TRAIL tumor apoptosis
Treatment of the leukemia C1498 or the renal carcinoma Renca with PS-341 significantly increased the sensitivity of these cells to cytolysis by TRAIL as assessed by either 18 hour isotope release or MTS staining assays (Figure 1a-1b) . Concentrations of PS-341 between 5-40 nM dramatically sensitized tumor cells to TRIAL-induced apoptosis, and under the conditions used in these experiments, the concentration of TRAIL required for maximal lysis of C1498 cells was 1000-2000 ng/ml (data not shown). In addition, similar results were obtained using Annexin V and propiduim iodide staining as a measure of cell death in 18 hour assays ( Figure 2 ). Tumor cells treated with PS-341 plus TRAIL also exhibited many of the morphological characteristics of apoptosis (data not shown). Furthermore, the caspase inhibitor zVAD-FMK was able to significantly reduce (Renca) or completely abolish (C1498) the effects of PS-341 plus TRAIL (Figure 3 ). This indicates that the cell death for both tumors was dependent on caspase activation.
Although these short-term assays did show a synergistic interaction between PS-341 and TRAIL (isobologram analysis, data not shown), we had previously noted that high doses (>100 nM) of PS-341 alone could cause significant death of these tumor cells usually 48 hours after exposure of tumor cells to the proteasome inhibitor. In order to determine whether the combination of PS-341 plus TRAIL was indeed superior to PS-341 alone, we compared the effects in 18 hours exposure of tumor cells to these agents, alone and in combination, on the long-term clonal survival of C1498 cells in liquid culture. Therefore after 18 hours of exposure only.
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Proteasome inhibition in tumor cells
We determined the extent of proteasome inhibition that occurred when PS-341 sensitized C1498
and Renca tumor cells to TRAIL-mediated cytolysis. As seen in Figure 4 
PS-341 effects on NF-B
One major effects of proteasome inhibition in many cells is the inhibition of NF-B translocation to the nucleus, due to blocking of the cytosolic degradation of I -B. Indeed this is thought to be the major mechanism whereby PS-341 sensitizes tumor cells to apoptosis. In order to assess the effects of PS-341 on NF-B activation, we transfected C1498 cells with an NF-B reporter construct coupled to luciferase to estimate levels of activated NF-B. After a rest period of 36 hours the transfectants were pretreated for 2 hours with PS-341 followed by a 4 hour incubation in the presence or absence of TRAIL. As seen in Figure 5a 
Effects of PS-341 on levels of antiapoptotic proteins
A number of proteins have been reported to block the apoptotic cascade. 10 We therefore treated (Figure 8b ). In contrast >90% of mice receiving the bone marrow: tumor cell mix treated with PS-341 plus TRAIL survived > 100 days which was a highly significantly increase in survival (p< 0.001) as compared to untreated mixtures, with up to 50% of mice surviving >100 days (Figure 8b ). In contrast >90% of mice receiving the bone marrow: tumor cell mix treated with PS-341 plus TRAIL survived > 100 days which was a highly significantly improvement (p<0.001) over PS-341 alone. Since the mice survived >100 days, this made it unlikely that PS-341 plus TRAIL had major detrimental effects on bone marrow cells in the inoculum. However, in order to examine the effects of PS-341 plus TRAIL on hematopoietic reconstitution in more detail, cellular blood counts (CBCs) were monitored in B6 mice at various time points after they received PS-341 plus TRAIL-treated bone marrow. There were some only.
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CBCs had normalized in all groups. Therefore the major bone marrow toxicity of PS-341 plus TRAIL was a mild, transient thrombocytopenia observed early after bone marrow transfer, which disappeared over time.
It remained important to determine whether the reconstitution of the immune system of the irradiated recipient mice had occurred due to the transfer of donor hematopoietic cells. only.
Discussion
Proteasome inhibition with specific inhibitors such as PS-341 is currently being used as a novel anticancer therapy in ongoing clinical trials. 30 Furthermore, PS-341 has shown efficacy in variety of tumor models both as a single agent 1 or in combination with chemotherapy 31, 32 or radiation therapy. 33 In this study we report that PS-341 can be successfully combined with the death ligand TRAIL to synergistically promote tumor cells apoptosis.
From our studies on the acute myeloid leukemia C1498, we could not conclude that the inhibition of NF-B was involved in the sensitization of these cells to apoptosis mediated by TRAIL. On examination of levels of several antiapoptotic genes, we only saw a substantial reduction in c-FLIP at concentrations of PS-341 that sensitize cells to TRAIL apoptosis.
Interestingly, the transcription of c-FLIP is not regulated by NF -B in all tumor cells. 15 Furthermore, in some studies major reductions of c-FLIP protein seem to occur at the posttranslational level. 34 It seems surprising that proteasome inhibition can cause a decrease in c-FLIP, particularly since c-FLIP is reported to be degraded by the proteasome in some cells. In the bone marrow purging model used in this study, the combination of PS -341 and TRAIL could selectively deplete C1498 tumor cells from bone marrow; tumor cell mixtures.
Although a slight thrombocytopenia was observed at early time points (day 14) following transfer of PS-341 plus TRAIL treated bone marrow, all cellular blood counts had normalized by day 60. It has been reported that PS-341 as a single agent has only minor effects in bone marrow function at doses used in tumor therapy in mice or rats. 1 In the clinical setting, PS-341 has been reported to have minimal effects on hematopoiesis, and only elicits a small transient thrombocytopenia. The mild thrombocytopenia seen here in mice did not appear to be problematic, and is similar to that seen in patients. In vitro studies indicate that TRAIL has either very minor or undetectable effects on hematopoesis in normal human bone marrow. 39, 40 We observed no effects of TRAIL as a single agent on hematopoesis in our studies. One important consideration is that not all tumors undergo apoptosis after exposure to TRAIL. Some solid tumors such as breast cancer and melanoma are reported to be sensitive to TRAIL-mediated apoptosis in vitro, 17, 44 whereas other tumor cells are resistant. In some cases (such as C1498) sensitivity can be increased by PS-341, whereas in other cases PS-341 has no effect (data not shown). Prior knowledge of the tumors' sensitivity to the PS-341 plus TRAIL treatment could therefore be a good advance predictor of the potential for the success or failure of treatment in a bone marrow transplantation setting. Our present studies have demonstrated only.
For personal use at PENN STATE UNIVERSITY on February 20, 2013. bloodjournal.hematologylibrary.org From substantial therapeutic benefits of PS-341 plus TRAIL in the BMT setting. It remains critical to determine whether PS-341 plus TRAIL can provide therapeutic benefit after systemic administration to mice bearing leukemias or solid tumors. TRAIL is reported to be far less toxic than other members of the TNF family on administration in vivo. 45 However there are reports that TRAIL does have significant toxicity to hepatocytes 46 and same neurological toxicity. 47 The concentrations of PS-341 required to sensitize C1498 or Renca cells to TRAIL-mediated lysis can be well tolerated in mice and humans. 1, 30 Indeed, the level of proteasome inhibition seen in the present study, and its reversal over time, mimic other data previously reported in vivo and from clinical data sets. This highlights the predictive nature of the 20S assay and its utility across in vitro, in vivo and human studies. 28 However, it remains crucially important to determine whether PS-341 plus TRAIL can be directly promote tumor destruction after direct administration of both agents to mice, and what the limiting toxicities of this combination would be. Systemic administration of PS-341 plus TRAIL could be used to destroy certain tumor cells directly, or alternatively to destroy the residual tumor cells remaining after high dose chemotherapy or radiation therapy regimens. In conclusion, these studies do indicate that the targeting of apoptotic pathways in tumor cells, using combinations of agents that synergistically interact to preferentially promote tumor cell apoptosis, could hold substantial promise for cancer therapy in the future.
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